Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3) are sodium-dependent phosphate cotransporters in the apical membrane of the kidney's proximal tubule, where they reclaim most of the phosphate filtered by the glomerulus and set your blood phosphate level. NaPi-IIa moves three sodium ions per phosphate and is rapidly removed from the membrane and degraded when parathyroid hormone or FGF23 rises, while NaPi-IIc is electroneutral, more abundant in infancy, and central to inherited phosphate wasting such as HHRH. Diet, vitamin D, klotho, acid-base status, and mutations in either gene shift how much phosphate is kept or lost, so symptoms can range from bone pain and muscle weakness to kidney stones and nephrocalcinosis. There are several important factors to consider, and the details below explain how each transporter is regulated and what disrupted balance can look like.
If low energy, aching bones, weakness, or stone-related pain has you wondering what is driving it, a free, instant, online symptom check can help you organize your symptoms, see which conditions fit the pattern, and understand which tests or specialist to ask about next.
Last reviewed for medical accuracy: 08/18/2026
Phosphate is vital for bone health, energy metabolism, cell signaling and acid-base balance. The kidneys filter and reabsorb roughly 80–90% of circulating phosphate to keep blood levels in a narrow range. Two key “proximal tubule brush border phosphate cotransporters,” NaPi-IIa and NaPi-IIc, do the heavy lifting. Understanding how they work and are regulated can shed light on disorders ranging from kidney stones to rickets.
• Bone mineralization
• ATP production and energy transfer
• DNA/RNA backbone stability
• Cell signaling (e.g., phosphorylation cascades)
• Buffering of blood pH
Imbalances can lead to muscle weakness, bone pain, cardiac issues and neurologic symptoms. The kidneys adapt phosphate reabsorption to diet, hormones and other signals.
• Stoichiometry: 3 Na⁺ : 1 HPO₄²⁻
• Expression: Early proximal tubule segments (S1 and S2)
• Capacity: High-capacity transporter responsible for the bulk of phosphate reabsorption
• Turnover: Rapid insertion/removal from the membrane in response to hormones
• Stoichiometry: 2 Na⁺ : 1 HPO₄²⁻
• Expression: Mid-proximal tubule (mainly S2 segment)
• Role: Lower capacity than NaPi-IIa but contributes significantly, especially in children
• Genetic link: Mutations lead to hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
The kidney adapts phosphate reabsorption rapidly and precisely by trafficking these cotransporters in and out of the brush border.
Disruption of these cotransporters or their regulators causes:
• Hypophosphatemia
– Muscle weakness, bone pain, rickets, osteomalacia
– Seen in PTH excess, Fanconi syndrome, HHRH (NaPi-IIc mutations)
• Hyperphosphatemia
– Soft tissue calcifications, cardiovascular disease
– Common in chronic kidney disease (CKD) due to reduced glomerular filtration and secondary increases in PTH/FGF23
• Genetic disorders
– Mutations in SLC34A1 or SLC34A3 → hereditary hypophosphatemic rickets
– Fanconi syndrome → generalized proximal tubule reabsorption defect
If you experience persistent bone pain, muscle weakness, fatigue or signs of mineral imbalance, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to gather insights and decide if you need medical evaluation.
This overview highlights the critical role of proximal tubule brush border phosphate cotransporters NaPi-IIa and NaPi-IIc in maintaining phosphate balance. However, any persistent or severe symptoms—especially those involving muscle function, bone health, or altered mental status—should prompt you to speak to a doctor immediately. Early evaluation and treatment can prevent complications and preserve long-term health.
(References)
* Levi M. Post-transplant hypophosphatemia. Kidney Int. 2001 Jun;59(6):2377-87. doi: 10.1046/j.1523-1755.2001.00755.x. PMID: 11380848.
* Kronenberg HM. NPT2a--the key to phosphate homeostasis. N Engl J Med. 2002 Sep 26;347(13):1022-4. doi: 10.1056/NEJMe020098. PMID: 12324560.
* Hernando N, Gisler SM, Pribanic S, Déliot N, Capuano P, Wagner CA, Moe OW, Biber J, Murer H. NaPi-IIa and interacting partners. J Physiol. 2005 Aug 15;567(Pt 1):21-6. doi: 10.1113/jphysiol.2005.087049. Epub 2005 May 12. PMID: 15890704; PMCID: PMC1474164.
* Kempe DS, Dërmaku-Sopjani M, Fröhlich H, Sopjani M, Umbach A, Puchchakayala G, Capasso A, Weiss F, Stübs M, Föller M, Lang F. Rapamycin-induced phosphaturia. Nephrol Dial Transplant. 2010 Sep;25(9):2938-44. doi: 10.1093/ndt/gfq172. Epub 2010 Apr 5. PMID: 20368307.
* Bergwitz C, Jüppner H. Phosphate sensing. Adv Chronic Kidney Dis. 2011 Mar;18(2):132-44. doi: 10.1053/j.ackd.2011.01.004. PMID: 21406298; PMCID: PMC3059779.
* Lederer E. Renal phosphate transporters. Curr Opin Nephrol Hypertens. 2014 Sep;23(5):502-6. doi: 10.1097/MNH.0000000000000053. PMID: 25028980; PMCID: PMC4361807.
* Saito A, McCormack FX. Pulmonary Alveolar Microlithiasis. Clin Chest Med. 2016 Sep;37(3):441-8. doi: 10.1016/j.ccm.2016.04.007. Epub 2016 Jun 24. PMID: 27514591; PMCID: PMC4987712.
* Murer H, Biber J, Forster IC, Werner A. Phosphate transport: from microperfusion to molecular cloning. Pflugers Arch. 2019 Jan;471(1):1-6. doi: 10.1007/s00424-018-2245-6. Epub 2018 Dec 19. PMID: 30569199.
* Xue J, Thomas L, Dominguez Rieg JA, Rieg T. Sodium phosphate cotransporter 2a inhibitors: potential therapeutic uses. Curr Opin Nephrol Hypertens. 2022 Sep 1;31(5):486-492. doi: 10.1097/MNH.0000000000000828. Epub 2022 Jul 18. PMID: 35894284; PMCID: PMC9387751.
* Lovegrove CE, Goldsworthy M, Haley J, Smelser D, Gorvin C, Hannan FM, Mahajan A, Suri M, Sadeghi-Alavijeh O, Moochhala SH, Gale DP, Carey D, Holmes MV, Furniss D, Thakker RV, Howles SA. Genetic variants predisposing to an increased risk of kidney stone disease. J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI186915. Epub 2025 May 15. PMID: 40372791; PMCID: PMC12321396.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.